Thomas Flaig, MD, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

Thomas Flaig, MD, University of Colorado Anschutz Medical Campus

Caption

Thomas Flaig, MD, is national primary investigator on clinical trial showing 13 percent response to abiraterone acetate in metastatic prostate cancer patients previously non-responding to hormone therapy

Credit

University of Colorado Cancer Center

Usage Restrictions

With attribution

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.